TCR-like antibodies in cancer immunotherapy

Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antib...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qinghua, Liu, Zhaoyu, Liu, Zhihua, Lai, Yuxiong, Zhou, Xinke, Weng, Jinsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744646/
https://www.ncbi.nlm.nih.gov/pubmed/31521180
http://dx.doi.org/10.1186/s13045-019-0788-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744646/
https://www.ncbi.nlm.nih.gov/pubmed/31521180
http://dx.doi.org/10.1186/s13045-019-0788-4

Ejemplares similares